跳至主要内容
临床试验/NCT07187063
NCT07187063招募中不适用

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

Lahey Clinic2 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2025年1月1日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
Lahey Clinic
入组人数
56
试验地点
2
主要终点
Number of cystoscopies

研究概览

简要总结

The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • AUA high-risk bladder cancer1
  • Received induction BCG or gemcitabine/docetaxel
  • Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)

排除标准

  • High-risk NMIBC within 3 years
  • Prior induction intravesical therapy
  • Variant histology
  • Concurrent upper tract disease

结局指标

主要结局

Number of cystoscopies

时间窗: From enrollment to 24 months

The rate of cystoscopies (cystoscopies per month), compared between the De-intensified and the standard surveillance arms, is the primary outcome measure.

次要结局

  • Event-free survival(From enrollment to 24 months)
  • Recurrence-free survival(From enrollment to 24 months)
  • Patient-reported outcomes(From enrollment to 24 months)

研究者

发起方
Lahey Clinic
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验